Mnohočetný myelom a další
monoklonální gamapatie
- prof. MUDr. Zdeněk Adam, CSc., Interní hematoonkologická klinika FN Brno, Brno
A randomised phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a duality-of-life assesment: the National Cancer Institute od Canada Clinical Trials Group Myeloma 10 Trial
Otevřít | 2013 | prof. MUDr. Zdeněk Adam, CSc.
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
Otevřít | 2010 | MUDr. Jana Gombošová
Monoclonal gammapathy of undetermined significance: a consensus statement
Otevřít | 2010 | MUDr. Marie Langová
Melphalan 200 mg/m2 versus melphalan 100 mg/m2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study
Otevřít | 2010 | MUDr. Petr Szturz
A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma
Otevřít | 2010 | MUDr. Petr Szturz
VMP (bortezomib, melphalan, and prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study
Otevřít | 2009 | MUDr. Petr Szturz
International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma
Otevřít | 2009 | MUDr. Petr Szturz
Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial
Otevřít | 2008 | MUDr. František Folber
Lenalidomide plus dexametasone for relapsed or refractory multiple myeloma
Otevřít | 2008 | MUDr. František Folber
Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexametasone compared with dexametasone as initial therapy for newly diagnosed multiple myeloma
Otevřít | 2008 | MUDr. František Folber
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
Otevřít | 2008 | MUDr. František Folber
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis
Otevřít | 2008 | MUDr. František Folber
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
Otevřít | 2008 | MUDr. František Folber
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression
Otevřít | 2008 | MUDr. František Folber
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
Otevřít | 2008 | MUDr. František Folber
Clinicopathological definition of Waldenström´s macroglobulinaemia: Consensus Panel Recommendation from the Second International Workshop on Waldenström´s macroglobulinemia.
Otevřít | 2008 | Prof. MUDr. Zdeněk Adam, CSc.
Plasma exchange when myeloma presents as acute renal failure
Otevřít | 2008 | Prof. MUDr. Zdeněk Adam, CSc.
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomized controlled trial
spojeno s:
Superiority of melphalane prednisone (MP) + thalidomid over MP and autologous stem cell transplantation in the treatment of newly diagnose elderly patients with multiple myeloma
Otevřít | 2006 | Prof. MUDr. Zdeněk Adam, CSc.